Thryv Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
999 Blvd. De Maisonneuve West Ste 1250, ...Phone Number
(514) 973-0915Website
www.thryvtrx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About Thryv Therapeutics
Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase.Explore more
Thryv Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Thryv Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Thryv Therapeutics
Earning: See what the market has to say on Thryv Therapeutics recently announced quarterly report
Check out if Thryv Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Thryv Therapeutics has new funding data
Product Launch: Get notified when Thryv Therapeutics launches new products
Check if Thryv Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Thryv Therapeutics had a recent Job posting/layoffs
Thryv Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Thryv Therapeutics
Compare insights from companies similar to Thryv Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$5.4M
11-50
Private
$230M
-
DD
D. Michael DixonChief Financial Officer and Chef De La Direction Financière
Company Profile Activity
Activity Insights
Thryv Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Thryv Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Thryv Therapeutics.
Thryv Therapeutics Tech Stack
A closer look at the technologies used by Thryv Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Thryv Therapeutics News & Media
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268
Patient dosing commenced in Wave II, a multicenter Phase 2/3 study evaluating THRV-1268 in genetically confirmed Long QT Syndrome (LQTS) Type 2; enrollment at leading centers throughout the United States is advancing on track. FDA Fast Track Designation granted for THRV-1268 in LQTS Type...Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and reinforced by significant QTcF reductions observed in a subsequent clinical study with...Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants
Study demonstrated clear target engagement at both tested doses Potential for THRV-1268 to address prolonged QTcF in cardiometabolic diseases Phase 2a ASPIRE-HF study to commence enrollment in 2026 MONTREAL, Dec. 17, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage...Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer
MONTREAL, Dec. 2, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Thryv Therapeutics
Sign Up For FreeTo access detailed company insights
Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase.... Read More
